| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Sangamo Biosciences, Inc. |
| 501 Canal Boulevard, Suite A100, Richmond, CA 94804 * (510) 970-6000 |
| Business Description | The company is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. |
| Offering Information Company has | |||
| Trading As | SGMO (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/11/00 |
| Domestic Shares Offered | 3,500,000 | Offer Date | 4/5/00 |
| Foreign Shares Offered | 0 | Filing Range | $15.00 - $17.00 |
| Company Shares | 3,500,000 | Offer Price | $15.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.050 |
| Gross Proceeds | $52,500,000 | Selling | $0.610 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 22,300,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 526-8100 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| ING Baring Furman Selz | Co-manager | (212) 309-8200 |
| William Blair & Company | Co-manager | (312) 364-8990 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 1.152 | 2.038 | 2.182 | - | - |
| Income from Oper. | - | - | -0.970 | -3.048 | -3.483 | - | - |
| Net Income | - | - | -0.926 | -2.875 | -3.352 | - | - |
| E.P.S | - | - | -0.170 | -0.490 | -0.560 | - | - |
| Revenue Growth (%) | - | - | 76.91 | 7.066 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -2.44 | - | - | ||||
| Cash Flow - Inv. | -6.01 | - | - | ||||
| Cash Flow - Fin. | 7.46 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 9.29 | Current Assets | 8.24 | Current Ratio | 8.00 |
| Total Liab. | 1.28 | Current Liab. | 1.03 | Debt Ratio | 13.78% |
| Total Equity | 8.01 | Working Cap. | 7.21 | Debt to Equity Ratio | 0.16 |
| Cash | 0.25 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development, repayment of a note and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Brobeck, Phleger & Harrison |
| Bank's Law Firm | Latham & Watkins |
| Registrar/Transfer Agent | EquiServe |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Edward O. Lanphier II | 24.70 | |
| Lombard Odier & Cie | 15.40 | |
| Entities Affiliated with JAFCO Co., Ltd. | 15.40 | |
| Stephens-Sangamo BioSciences LLC | 12.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||